Key Segmentation
By Type
-
Generic
-
Innovative
By Type of Manufacturers
-
In-house
-
Outsourced
By Synthesis Technology
-
Solid Phase Peptide Synthesis
-
Liquid Phase Peptide Synthesis
-
Recombinant DNA Technology
By Route of Administration
-
Parenteral
-
Oral
-
Pulmonary
-
Mucosal
-
Others
By Application
-
Oncology
-
Metabolic Disorders
-
Cardiovascular
-
Infectious Diseases
-
Others
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Peptide Therapeutics Market is expected to grow at a CAGR of 7.51% from 2026 to 2035.
The Peptide Therapeutics Market was valued at USD 49.50 billion in 2025.
The rising global burden of chronic diseases particularly metabolic disorders, oncology, and cardiovascular conditions combined with the clinical validation of peptide based targeted therapies, rapid advances in synthesis technology, and the extraordinary commercial momentum of GLP-1 receptor agonist peptide therapies are the primary structural drivers of sustained market growth through 2035.
The Recombinant DNA Technology segment dominated the Peptide Therapeutics Market in 2025 with approximately 64.3% of global synthesis technology revenue, reflecting its superior suitability for producing complex long chain therapeutic peptides with consistently high purity and biological activity at commercial scale.
North America dominated the Peptide Therapeutics Market in 2025 with approximately 44% of global market revenue, led by the United States whose combination of world class pharmaceutical R&D infrastructure, FDA regulatory leadership, strong insurance reimbursement frameworks, and extraordinary commercial demand for GLP-1 metabolic peptide therapies positions it as the most valuable single national market in the global peptide therapeutics industry.